<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3248">
  <stage>Registered</stage>
  <submitdate>26/07/2011</submitdate>
  <approvaldate>26/07/2011</approvaldate>
  <nctid>NCT01403636</nctid>
  <trial_identification>
    <studytitle>A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia</studytitle>
    <scientifictitle>A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2011-001616-57</secondaryid>
    <secondaryid>ARD12130</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Lymphoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - SAR245409

Experimental: mantle cell - 50 mg twice daily: no eating for 2 hours prior and 1 hour after dose

Experimental: follicular lymphoma - 50 mg twice daily: no eating for 2 hours prior and 1 hour after dose

Experimental: CLL/SLL - 50 mg twice daily:no eating for 2 hours prior and 1 hour after dose

Experimental: Diffuse large B cell lymphoma - 50 mg twice daily:no eating for 2 hours prior and 1 hour after dose


Treatment: drugs: SAR245409
Pharmaceutical form:capsule Route of administration: oral

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Objective response rate (ORR) as defined as the proportion of patients who experience complete response/remission (CR) or partial response/remission (PR)</outcome>
      <timepoint>2 months to 2 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Progression free survival (PFS) at 6 months</outcome>
      <timepoint>6 months to 2 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          -  Tissue from an archived or fresh tumor sample

          -  A peripheral blood buffy coat sample is required for CLL/SLL.

          -  Patient has mantle cell lymphoma (MCL), follicular lymphoma (FL), or chronic
             lymphocytic leukemia (CLL)/SLL or diffuse large B cell lymphoma

          -  Patient &gt; or = 18 years old

          -  Eastern Cooperative Oncology Group (ECOG) performance status &lt; or = 2. Patients with
             DLBCL will have ECOG &lt; or = 1

          -  Adequate white blood cells and hemoglobin

          -  Good kidney and liver function

          -  Fasting glucose &lt; 160 mg/dL

          -  No other malignancy

          -  Use of adequate birth control</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  Treatment with cytotoxic chemotherapy, biologic agents, investigational therapies
             within 4 weeks, or nitrosoureas or mitomycin C within 6 weeks of study enrollment

          -  Treatment with a small-molecule kinase inhibitor within 2 weeks, or 5 half lives of
             the drug or its active metabolites (whichever is longer) of study enrollment

          -  Prior treatment with a PI3K, mTOR, or Akt inhibitor. Prior treatment of MCL with
             temsirolimus is permitted in patients enrolled from countries where it is licensed for
             this indication.

          -  Radiation therapy within 2 weeks of enrollment

          -  Autologous stem cell transplantation within 16 weeks of enrollment

          -  Prior allogeneic transplantation except for patients with R/R DLBCL who meet inclusion
             criteria

          -  Central nervous system (CNS) or leptomeningeal involvement. Patients with DLBCL may
             have active CNS or leptomeningeal involvement.

          -  Positive Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody (anti-HCV)
             serology

          -  Primary CNS lymphoma

          -  Primary mediastinal B-lymphoma

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>167</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Investigational Site Number 036002 - Clayton</hospital>
    <hospital>Investigational Site Number 036001 - Hobart</hospital>
    <hospital>Investigational Site Number 036005 - Kingswood</hospital>
    <hospital>Investigational Site Number 036003 - Perth</hospital>
    <postcode>3168 - Clayton</postcode>
    <postcode>7001 - Hobart</postcode>
    <postcode>2747 - Kingswood</postcode>
    <postcode>6000 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>West Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pierre Benite Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rennes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rouen Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villejuif Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt Am Main</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Jena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ulm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Groningen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Sanofi</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Primary Objective:

      - To evaluate the efficacy of SAR245409 as determined by the objective response rate (ORR) in
      patients with 1 of following relapsed or refractory lymphoma or leukemia subtypes: mantle
      cell lymphoma (MCL), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL)/small
      lymphocytic lymphoma (SLL), or diffuse large B cell lymphoma (DLBCL)

      Secondary Objectives:

        -  To assess duration of response, progression free survival (PFS), and proportion of
           patients with PFS at 6 months (24 weeks) in patients with either MCL, FL, CLL/SLL or
           DLBCL treated with SAR245409

        -  To evaluate the safety and tolerability of SAR245409 in patients with MCL, FL, CLL/SLL
           or DLBCL

        -  To further characterize the plasma pharmacokinetics (PK) of SAR245409 in patients with
           MCL, FL, CLL/SLL or DLBCL</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01403636</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Sciences &amp; Operations</name>
      <address>Sanofi</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>